Maintenance window scheduled to begin at February 14th 2200 est. until 0400 est. February 15th

(e.g. yourname@email.com)

Forgot Password?

    Defense Visual Information Distribution Service Logo

    World AIDS Day Event Highlights DOD Contributions in Fight Against HIV Pandemic

    MARYLAND, UNITED STATES

    12.05.2019

    Courtesy Story

    Walter Reed Army Institute of Research

    The Walter Reed Army Institute of Research (WRAIR) hosted a World AIDS Day event Tuesday, Nov. 26, highlighting advances in DOD-led HIV research and celebrating the 10th anniversary of the Army-led RV144 HIV vaccine study.

    WRAIR’s Military HIV Research Program headed the RV144 “Thai study,” the first-ever – and only to-date – clinical trial to demonstrate an HIV vaccine regimen was safe and modestly effective in preventing HIV infection. The RV144 trial represented a massive undertaking for the Army and serves as a model of international and interagency collaboration.

    The trial involved more than 16,000 adult volunteers and a large network of partners who still collaborate with WRAIR today, including the Thai Ministry of Public Health, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and Sanofi Pasteur. The linked video featuring many prominent HIV researchers who were involved with RV144 was shown at the World AIDS Day event.

    In Fall 2009 the Army announced that the investigational prime-boost vaccine regimen lowered the rate of HIV infection by 31.2 percent. These results, though modest, gave the global community hope that a vaccine to prevent HIV infection is possible at a time when such an achievement seemed elusive.

    “RV144 was the light at the time in the field, without which we may have given up,” said Dr. John Mascola, Director of the National Institutes of Health Vaccine Research Center and the featured speaker at WRAIR’s World AIDS Day event. “In the last 10 years of HIV vaccine progress, RV144 is the anchor.”

    The landmark trial continues to provide scientific direction to help guide vaccine development and testing. RV144 and its follow-on trials allowed researchers to discover correlates of risk, provide targets for optimizing vaccine boosting, and form a foundation for three HIV vaccine candidates currently undergoing efficacy testing.

    NEWS INFO

    Date Taken: 12.05.2019
    Date Posted: 12.05.2019 13:58
    Story ID: 354429
    Location: MARYLAND, US

    Web Views: 44
    Downloads: 0

    PUBLIC DOMAIN